46 results about "Kallikrein" patented technology

Compositions and methods for editing, e.g., introducing double-stranded breaks, within the KLKB1 gene are provided. Compositions and methods for treating subjects having hereditary angioedema (HAE), are provided.

The present application provides an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein (for example, PSA or hK2) for use in the treatment of prostate cancer, and a method for the treatment of prostate cancer in a patient, the method comprising the step of administering a therapeutically effective amount of an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein to the patient.

The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more compounds of Formula I compounds, and methods for using the compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.

The present invention provides compositions and methods for inhibiting thrombosis in subjects at risk of thrombosis, such as those with a genetic, acquired, or environmental risk of thrombosis. [Solution] The present invention provides RNAi agents, such as double-stranded RNAi agents, that target kallikrein B, plasma (Fletcher factor) 1 (KLKB1) gene, factor XII (Hageman factor (F12) gene, or kininogen 1 (KNG1) gene, as well as methods for inhibiting the expression of the KLKB1 gene, F12 gene, and / or KNG1 gene using such RNAi agents, and methods for treating subjects with hereditary angioedema (HAE) and / or contact activation pathway-related disorders.

The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg9-Bradykinin and des-Arg10-Kallidin-like peptide.

The application belongs to the technical field of cosmetics and skin external preparation, and discloses a retinoid, a preparation method and application thereof. The compound is formed by covalently coupling a Schiff base or a kinin releasing enzyme cleavable peptide bond (L) and a free L-amino acid, a di- to hexapeptide or a C6-C22 fatty acid ester (P) of the retinol parent (R), and the structural general formula is R-L-P. The compound has a 12-week stability rate of ≥80% in a 25℃ aqueous preparation, is recognized by a keratin layer carboxylic acid esterase and a kinin releasing enzyme KLK-5 / KLK-7 after being applied to the skin, is subjected to enzymatic cutting in a skin acidic cuticle (pH 4.5-5.5) microenvironment, and releases free retinol at a fixed point. Compared with retinol palmitate, the in-situ release efficiency of the compound of the application is increased by 2.5-4.5 times, while the risk of systemic absorption is significantly reduced, and the incidence of sensitive skin irritation is ≤6.7%.

Aspects of the application provide dual inhibitor anti-KLK5 / KLK7 antibodies and methods of using the same for promoting barrier function and reducing inflammation, and treating conditions such as Netherton syndrome, eosinophilic esophagitis and atopic dermatitis.

Provided herein are plasma kallikrein binding proteins such as antibodies binding to active plasma kallikrein and methods of using such proteins in treating hereditary angioedema.

Plasma kallikrein binding proteins and methods of using such proteins are described.

Materials, methods, and systems for enhanced protease targeting. For example, methods for the targeting of kallikrein related peptidase 2 (KLK2) are provided.

The invention relates to screening and application of a chronic kidney disease plasma protein marker, and belongs to the technical field of plasma protein markers. The protein marker combination comprises 25 proteins such as de-integrin metalloproteinase 22, keratinoin, chitosanase 3-like protein 1, an XVIII type collagen alpha 1 chain, a VI type collagen alpha 3 chain, a growth differentiation factor 15, phospholipid globulin glycan 1, a renal injury factor 1, histidine-rich calcium binding protein, kallikrein related peptidase 4 and the like which are positively correlated with the chronic kidney disease. The kit also comprises seven proteins such as a contact protein 5, an Erb-b2 receptor tyrosine kinase 3, an Erb-b2 receptor tyrosine kinase 4, an insulin-like growth factor binding protein 3 and the like which are negatively related to the chronic kidney disease. Compared with previous cross section research or case contrast research, the protein related to chronic kidney disease incidence can be screened, and the causal time sequence of the protein and chronic kidney disease is clearer.

The problem to be solved by the present invention is to provide an extract of bacteria of the genus Sphingomonas, which may be used as an inhibitor of the kallikrein-kinin system and can reduce the occurrence of redness.SOLUTION: The present invention relates to an extract of bacteria of the genus Sphingomonas, to a composition comprising at least one bacterium of the genus Sphingomonas or said extract, to the uses thereof and to the implementation thereof in a cosmetic method.SELECTED DRAWING: None

Disclosed herein are polypeptides that are useful for, among other things, inhibiting or suppressing the activity of a kallikrein-related protease and therefore treating diseases and conditions involving dysregulated kallikrein-related protease activity. Pharmaceutical compositions and therapeutic methods using the polypeptides and pharmaceutical compositions are also provided.

The present application relates to the preparation of new physiological and pharmaceutically active molecules, and belongs to the field of pharmaceutical synthesis chemistry, and relates to the design and preparation of a class of molecules capable of inhibiting the activity of human kallikrein. Firstly, fluoroacrylic acid and alcohol compounds are used as raw materials to obtain a class of fluoroallyl alcohol compounds; then the fluoroallyl alcohol is condensed with carboxylic acid compounds to obtain fluoroallyl carboxylic acid ester compounds with general formula (I) capable of inhibiting the activity of human kallikrein. The compounds are considered to be useful for treating diabetic complications, eye diseases and edema-related diseases. In addition, they have potential applications in the diagnosis and treatment of some cancers.

The present disclosure provides antibodies and polypeptides that specifically bind to kallikrein related peptidase 6 (KLK6). Also provided are compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Aspects of this application provide anti-KLK5 antibodies, anti-KLK7 antibodies, and anti-KLK5 / KLK7 antibodies (e.g., bispecific antibodies), as well as methods of using them to promote barrier function, reduce inflammation, and treat conditions such as Netherton syndrome, eosinophilic esophagitis, and atopic dermatitis. Certain aspects of this disclosure relate to the recognition that a loss of balance between endogenous KLK proteases and associated protease inhibitors can lead to barrier dysfunction and induce inflammation (see, for example, Figure 1), which can result in inflammatory conditions, such as Netherton syndrome, eosinophilic esophagitis, and atopic dermatitis.

Provided is a non-human animal that is useful for analysis of a kallikrein-kinin system. A non-human animal that lacks the Kng1 gene and the Kng2 gene.

The application belongs to the technical field of daily chemicals, and provides a triple composite acid composition with skin lightening, skin rejuvenation and acne-removing effects, a product and application thereof, which comprises almond acid, salicylic acid and succinic acid, and the mass ratio of the almond acid, the salicylic acid and the succinic acid is 3-6:1-2:1-2. The application also provides a product containing the above composition and application thereof. The composition provided by the application is synergistically used, has a synergistic effect in terms of exfoliation, especially in terms of improving the activity of kallikrein 5 (KLK5), has not only the effects of biological skin rejuvenation and exfoliation, but also can efficiently down-regulate the expression of I-type 5alpha-reductase gene, thereby inhibiting the synthesis of sebum and playing an oil control role. In addition, the composition provided by the application has the effects of lightening, bacteriostasis and anti-inflammation, has low sensitization, can be used for acne removal, has rapid effect and is not repeated.

The present invention relates to a composition for preventing, improving, or treating inflammatory disease containing isookanin or a salt thereof as an active ingredient. The composition containing the isookanin or salt thereof as an active ingredient according to the present invention has no skin irritation and cytotoxicity, and thus has excellent safety for the human body. In addition, it has excellent effects on the inhibition of JAK1 activity, kallikrein-5 activity, TLR-2 activation, COX-2 expression and activity, prostaglandin PGE2 production, and PGE2-induced angiogenesis, and thus is very effective in preventing, alleviating and treating inflammatory disease. Accordingly, the composition containing the isookanin or salt thereof as an active ingredient according to the present invention may be useful as an active ingredient in a cosmetic composition, a pharmaceutical composition, a composition for skin application and a quasi-drug composition for preventing, alleviating or treating inflammatory disease.

Compositions and methods are provided for editing, e.g., introducing double-strand breaks, within the KLKB1 gene.Compositions and methods are provided for treating a subject with hereditary angioedema (HAE).

Aspects of the application provide anti-KLK5 antibodies, anti-KLK7 antibodies, and anti-KLK5xKLK7 antibodies (e.g., bispecific antibodies) and methods of using the same for promoting barrier function and reducing inflammation, and treating conditions such as Netherton syndrome, eosinophilic esophagitis and atopic dermatitis.

The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the Kallikrein B, Plasma (Fletcher Factor) 1 (KLKB1) gene, the Factor XII (Hageman Factor (F12) gene, or the Kininogen 1 (KNG1) gene, and methods of using such RNAi agents to inhibit expression of a KLKB1 gene, an F12 gene, and / or a KNG1 gene, and methods of treating subjects having an hereditary angioedema (HAE) and / or a contact activation pathway-associated disorder.

The invention belongs to the technical field of plasma protein markers, and discloses a plasma protein marker and a risk prediction system for a heart failure onset risk of a type 2 diabetes mellitus patient, and the protein marker combination is applied to preparation of a kit for predicting the heart failure onset risk of the type 2 diabetes mellitus patient. The protein marker combination comprises a C-C motif chemotactic factor 24, a C-C motif chemotactic factor 7, a carcino-embryonic antigen related cell adhesion molecule 6, a fiber gelling protein 1, a follistatin, a polypeptide N-acetylgalactosamino transferase 5, an ADP ribosylation factor binding protein GGA1, a kallikrein 4, a nerve bundle protein, renin, a plasma protease C1 inhibitor and cardiac troponin I, the brain natriuretic peptide comprises a brain natriuretic peptide precursor, an N-terminal brain natriuretic peptide precursor, apolipoprotein C1, tetramer connexin, a Mepin A beta subunit and multi-ligand proteoglycan-4. The invention further constructs a risk score and prediction model for predicting the attack risk of the heart failure of the type 2 diabetes mellitus patient based on the protein marker.

To provide a next-generation kallikrein-related peptidase 2 (hK2) binding domain for therapeutic and diagnostic purposes. [Solution] Embodiments of the present invention provide isolated proteins comprising an antigen-binding domain that binds to kallikrein-related peptidase 2 (hK2), including monospecific and bispecific antibodies. Additional embodiments of the present invention provide polynucleotides encoding hK2-specific proteins, vectors, host cells, and methods for producing and using them.

To provide anti- KLK7 antibodies, anti- KLK5 antibodies, anti- KLK5 / KLK7 multispecific antibodies, and methods of using the same.SOLUTION: Provided are isolated antibodies that bind to human kallikrein-related peptidase-7 (KLK7), wherein the antibodies inhibit human KLK7 mediated cleavage of a substrate comprising a particular amino acid sequence, and / or wherein the antibodies bind to human 10pM with a KD less than 9pM, or less than, or less than 8pM, or less than 7pM, or less than 6pM, or less than 5pM, and wherein the antibodies bind to a particular epitope of KLK7. KLK7.SELECTED DRAWING: Figure 19B

Compositions and methods for editing, e.g., introducing double-stranded breaks, within the KLKB1 gene are provided. Compositions and methods for treating subjects having hereditary angioedema (HAE), are provided.

Embodiments of the present invention provide isolated proteins comprising antigen binding domains that bind kallikrein related peptidase 2 (hK2), including monospecific and bispecific antibodies. Additional embodiments of the invention provide polynucleotides encoding the hk2-specific proteins, vectors, host cells, and methods of making and using them.

Aspects of the present application provide anti-KLK5 antibodies, anti-KLK7 antibodies, and anti-KLK5 / KLK7 antibodies (e.g., bispecific antibodies) and methods of using them to promote barrier function and reduce inflammation and to treat conditions such as Neethton Syndrome, eosinophilic esophagitis, and atopic dermatitis.

Compositions and methods for editing, e.g., introducing double-stranded breaks, within the KLKB1 gene are provided. Compositions and methods for treating subjects having hereditary angioedema (HAE), are provided.

The application belongs to the technical field of skin care, and discloses a soothing composition, application and skin care product, wherein the soothing composition comprises lactoferrin, oat extract and calcium gluconate, and the weight ratio of the lactoferrin, the oat extract and the calcium gluconate is 0.1-0.5:40-60:4-8; the application can play a significant inhibiting effect on the expression of kallikrein-related peptidase 7 gene by compounding the lactoferrin, the oat extract and the calcium gluconate, and can effectively improve the skin soothing effect of the composition by regulating the expression of the kallikrein-related peptidase 7 gene.